Prescription Drug Monitoring Program (PDMP)...What is a Prescription Drug Monitoring Program? • A...

Prescription Drug Monitoring Program (PDMP)

LOUISIANA

Information contained in this presentation is accurate as of September 2017

Meet the Speaker

Julie W. Breithaupt PharmD, MBAPresident Louisiana Pharmacists Association

2

What is a Prescription Drug Monitoring Program?

• A PDMP/PMP is a statewide electronic database which

collects designated data on specified substances dispensed

to or for patients. The PDMP is housed by a state regulatory,

administrative or law enforcement agency. The housing

agency disseminates information from the database to

individuals who are authorized under state law to receive

the information for purposes identified by state law.

3

State PDMP Overview

• Act 676 of the 2006 LA Legislature authorized the LA Board of Pharmacy

to develop, implement, and operate an electronic system for the

monitoring of controlled substances and other drugs of concern

dispensed in the state or to an address within the state.

• Goal – to improve the state’s ability to identify and inhibit the diversion

of controlled substances and other drugs of concern in an efficient and

cost-effective manner, a manner that shall not impede the appropriate

utilization of these drugs for legitimate medical purposes.

4

State PDMP Overview

5

Exceptions/Exclusions for Reporting

• Veterinarians are excluded.

• The LA Board of Pharmacy may issue an exemption from the reporting requirements to a dispenser whose practice activities are inconsistent with the intent of the program. The Board will only consider requests from dispensers who do not dispense controlled substances or drugs of concern.

6

Data Exchange Time Period

• Data must be submitted no later than the next business day after the date of dispensing controlled substances and other drugs of concern (including mail order)

• Reporting must be submitted to the data collection vendor in approved formats and frequencies.

○ If no applicable substances are dispensed for the preceding reporting period, the pharmacy must file a zero report for that reporting period or be considered non-compliant.

7

Approved Users

• Prescribers and dispensers of controlled substances and

drugs of concern, primarily to their own patients, with

the exception of veterinarians.

• These include physicians, podiatrists, dentists,

optometrists, APRNs, PAs, medical psychologists, and

every licensed pharmacy.

8

Mandates• It is the responsibility of the prescriber/dispenser to be aware of

updates/amendments to the legislation as they are enacted and promulgated.

• June 2017 updates include○ Requires the prescriber or delegate to access the PMP and review the

patient’s record prior to issuing the initial prescription for any opioid medication and, in the event the duration of therapy exceeds 90 days, then to access the PMP and review the patient’s record every 90 days.

○ Continuing education requirements – a minimum of 3 hours relative to drug diversion training, best practice in prescribing of controlled substances, appropriate treatment of addiction, or any similar topic deemed appropriate by the licensing board.

9

Limitations of Matching Data

• There are clustering algorithms built into the system to assist with patient-matching which are implemented/used by the software vendor.

• Recommendations for best searches are made available on the website in a Quick Reference Guide.

• Recommendations are also available in the PMP account for registered users.

10

Data Availability

• The PMP database for LA is available at https://louisiana.pmpaware.net

• Authorized users may access only their patients’ data

• Individual authorization of the patient is not required under HIPAA, 45CFR Sec

164.512(a)(d).

• Eligible prescription transactions (Schedules II through V and drugs of concern)

are submitted to the Appriss Clearinghouse. Drugs of concern include butalbital-

containing products that are not controlled. Ephedrine, pseudoephedrine, and

phenylpropanolamine-containing products are considered LA Schedule V.

11

Other State Databases

• The Patient Request (patient search) allows for a search in LA as well as 16 other

states: AL, AK, AR, CO, KS, MA, MI, MS, NV, ND, OK, PA, SC, SD, TN, and TX.

• If a registered user of the PMP Clearinghouse needs to submit data files to an

additional state using PMP Aware, the user can submit the request through their

account settings page.

• With recent legislative change facilitating the sharing of data with other states, we

continue to identify new states with which we can share prescription data.

12

Analytics

• MME/Active MME is now available for the prescriber/pharmacist.

• The registered user may pull a patient’s prescription history

report w/name, DOB, timeframe

○ Timeframe defaults to most recent 12 months– can go back 5 years

• There is an add-on service for risk scores

○ NARX Care

• Preparing to “turn on” interoperability with the electronic health

record system of a large health system.

13

Trends and Use Patterns

• The PMP monitors trends of users and use patterns. An annual report is

produced which provides summary data for the operational aspects of

the program – number of prescription transactions reported to the

program database, number of prescribers and dispensers and their

delegates registered to access the program data, the number of queries

performed by those authorized prescribers, dispensers and delegates, as

well as law enforcement agencies and regulatory agencies, and, finally,

the average number of queries per day.

14

State PDMP Moving Forward

• With a recent legislative change facilitating the

sharing of data with other states, we continue to

identify new states with which we can share

prescription data

○ 10-12 states in the next few months

• Prescriber report cards to be added

15

QIN-QIO Involvement

• Why work with your QIN-QIO?○ Access to data○ Coordinated Efforts

⁻ QPP Quality Measures & Improvement Activities

▪ Ex. Consultation of the PDMP (Activity ID: IA_PSPA_6)

○ Education and training○ Process Improvement

• Additional QIN-QIO Information: http://qioprogram.org/sites/default/files/resources/documents/QIN-QIO_Fact_Sheet_June2017_508.pdf

• Quality Insights contact – Kym Herrin

○ kherrin@eqhs.org

16

Thank you for watching!

• For more information about Louisiana’s Prescription

Monitoring Program, please contact:

○ Joe Fontenot R.Ph.

⁻ Assistant Executive Director, Louisiana Board of Pharmacy

⁻ jfontenot@pharmacy.la.gov

⁻ 225-922-0094

⁻ www.pharmacy.la.gov

17